Neoplasms, Rectal research hub

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

This study looks at a new drug called dostarlimab for people with a specific type of early rectal cancer (dMMR/MSI-H) who haven't had other treatments. The aim is to see if dostarlimab alone can help avoid chemotherapy, radiation, and surgery.